Dairy and Egg Protein Analogues Patents: Who Leads 2026
Dairy and Egg Protein Analogues Patents: Mapping the Recombinant Protein Race
One filer holds 26 of 31 records in scope — the field is dominated by a single leader rather than spread across a competitive set. Filing activity rose from zero in 2017 to a peak of 11 records in 2022, then declined; the 2021-to-2024 span shows a confirmed -17% move (6 to 5 records). Years after 2024 are still filling in under publication lag and should not be read as a continued slide.
- 1新培养公司83.9%
- 2克莱拉食品公司6.5%
- 3斯姆比克姆公司3.2%
- 4PLANTOPIA LTD3.2%
- 5FINALLY FOODS LTD3.2%
See the full dairy and egg protein analogues analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents on dairy and egg protein analogues?
One assignee holds 26 of the 31 records tracked in this landscape, making it the clear leader by a wide margin. The remaining four ranked assignees hold single-digit counts, down to one record for the fifth-ranked filer. This is a concentrated field rather than a broad competitive set, so any new filer’s claim strategy should be benchmarked against that leader’s portfolio specifically.
Is patent filing in this space growing or slowing down?
Filing peaked at 11 records in 2022 and then declined, with a confirmed drop of 17% between 2021 and 2024 (6 records down to 5). That is the most recent period that can be read reliably. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so it is too early to call the trend beyond 2024 a continued decline.
What does US20230404098A1 actually cover?
US20230404098A1, filed by New Culture Inc. and published in December 2023, covers dairy-like compositions made using one or more recombinant proteins, along with methods of producing them. It sits within a cluster of related filings sharing the same title and applicant lineage in this dataset, suggesting a family of continuation or divisional claims around the same core production approach. Anyone building a competing recombinant-casein or whey-analogue product should review this filing’s specific claim language on protein composition and production method before finalising a process design.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Dairy and Egg Protein Analogues covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.